Audit: QRS - Fermented Cod Liver Oil for Health & Longevity

Audit conducted on 09/09/2026 06:56 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: protocol cells to Therapeutic Protocol, time cells to Practical Considerations and Therapeutic Protocol, gates to Key Interactions & Contraindications, monitoring rows to the ER biomarker table.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No human study has tested the fermented product” mirrors the ER Conclusion; “declares no amount” mirrors “supplies an unlabelled amount”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy stays in Contraindications, retinoids stay absolute, the RA benefit stays framed as reduced drug requirement rather than disease improvement.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	All gate items come from Key Interactions & Contraindications; no Benefit-Modifying Factors or Risk-Modifying Factors entry appears in the gates or risk card.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, citations, expert names, NCT identifiers or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, sceptical register matching the ER’s handling of the disputed laboratory evidence.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Biomarker targets and cadence give the reader an actionable frame without exhortation.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol and monitoring cells describe standard practice rather than instructing.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Cadence is phrased descriptively (“Anyone on an anticoagulant adds a clotting check at 4 weeks”).
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “advise” or “should” constructions in the document’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the sheet.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms carried over are ER-verbatim biomarker and drug-class names; “filtering rate” replaces the ER’s fuller gloss of estimated glomerular filtration rate.
2.8	Information is presented in a concise and very compact manner	🟢	Every benefit, risk and gate item is a single noun phrase; no sentences longer than one clause outside the cadence line.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for “you”/”your”: no matches.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Seven-marker monitoring panel and fasting retinyl ester testing presume a proactive, self-testing reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Baseline plus 12-week plus 6–12-month testing schedule assumes willingness to test repeatedly.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified “ask your doctor” framing; the sheet assumes independent biomarker interpretation.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance foregrounds cumulative retinol accumulation, the hazard specific to decades of daily use rather than short-term intake.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears only in the ER-derived title; “anti-aging” appears nowhere.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical register throughout (“eructation”, “albumin-corrected serum calcium”, “fasting retinyl esters”); the single plain word “painkiller” in At-A-Glance is ER Conclusion wording required by the plain-language rule 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate headings and column headers are byte-identical to the template; retained tier labels read “Medium: “, “Low: “, “Speculative: “ unchanged.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Set comparison against the template: every named variable present; the marker_#_* and qualitative_item_# placeholders are correctly expanded to marker_1..7_* and qualitative_item_1..7.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template shows the three website= spans (evidence_review, audit, full_review), all CSS and all markup unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section drawn on by the QRS is empty; the two unpopulated tiers (benefits High, risks High) are governed by rules 12.5 and 13.5 instead.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Standard traditional-foods protocol”, “Best time of day”, “Single versus split dosing” are ER bold labels verbatim; caution items reuse the ER bold labels of the interaction bullets.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Monitoring marker names match the ER biomarker table verbatim; Time-to-Effect cell labels name the ER’s own three quantities rather than inventing categories.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Full-text scan returns zero tier or warning emoji; the ER’s “⚠️ Conflicted” markers were dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every list entry compressed to a single noun phrase and all magnitudes stripped; no section exceeds the template’s per-card budget.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1 and before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13; the title text on line 2 precedes the block.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no element in body repeats any metadata value.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: fermented_cod_liver_oil_2026-0909-0433_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0909-0643.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk: fermented_cod_liver_oil_2026-0909-0433_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Fermented Cod Liver Oil for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Fermented Cod Liver Oil for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/09/2026”, from qrs_creation_date: 2026-0909-0643.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block is structurally identical to the template; the ER’s “Also known as” line was not carried across.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all four Conclusion paragraphs into composition, evidence void, the one supported clinical effect and the dominant hazard.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Composition and “whole-food oil” from ER line 530; “No human study” from line 532; painkiller sparing and hip fracture from line 534; “declares no amount” from line 536.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “ready-made vitamin A”, “marine fats”, “inflammatory joint disease” and “painkiller” are all lay terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No study names, years or sample sizes appear.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items trace to that section: six to the “Populations who should avoid” list and the retinoid drug names to the “Oral retinoids” bullet marked “absolute contraindication”.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER avoid-list entries are present, none omitted and none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements inside the stop_items span (lines 540–546).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing rationales (“because ready-made retinol above 3,000 µg daily causes birth defects…”, “where added ready-made retinol works against treatment”) are stripped; no dashes remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“Child-Pugh Class B or C”, “stage 4 or 5 (filtering rate below 30 mL/min/1.73 m²)”, “above 10% of total vitamin A” and the four retinoid drug names are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication list uses no ranking notation; thresholds are written out in words (“above 10%”, “below 30 mL/min/1.73 m²”).
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map one-to-one onto the ER’s interaction bullets (lines 357–373).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The “Oral retinoids” bullet, an absolute contraindication, is correctly excluded here and carried in stop_items instead.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine <li> elements inside the caution_items span (lines 554–562).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	All ER mitigation sentences are stripped; the ER’s em-dash construction “Additive supplements — vitamin A, …” is normalised to parentheses with no trailing clause.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every named drug list is preserved verbatim, including the italicised Ginkgo biloba; only the MAOI bullet’s descriptive gloss is trimmed while its four drug names are kept.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction parentheticals are plain comma-separated drug lists with no ranking symbols.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten interactions and the section is correspondingly populated with the nine non-contraindication ones.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets at lines 407, 413 and 417.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing and dosing frequency — the three cells that determine how the oil is actually taken — rather than the ER’s comparative or modifier bullets.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section contains eleven bullets, well above three, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; e.g. action_1_value “2–5 mL daily” and action_1_sub “Half to one teaspoon of the liquid oil, taken year-round with food” both from ER line 407.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Joint symptom change, red-cell omega-3 and 25-hydroxyvitamin D — the exact three quantities given in the ER Practical Considerations “Time to effect” bullet (line 460).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	The joint-symptom cell corresponds to the only Medium-tier benefit and is placed first; the two biomarker cells correspond to Low-tier benefits and follow.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect intervals, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; time_3_sub “Circulating 25-hydroxyvitamin D turns over in two to three weeks” derives from the ER half-life bullet at line 415.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides an explicit “Time to effect” bullet, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every listed item is an ER Expected Benefits heading in its own tier; the one heading not carried across, “Prevention of Respiratory Infection”, is the entry whose ER net reading is that cod liver oil does not prevent respiratory infection, so listing it as a benefit would have breached rule 1.3.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 521–530.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the bare ER heading in sentence case; no magnitudes, confidence intervals or citations survive.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits entry.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	Line 521: <span data-qrs-var="benefits_high" style="display: none"></span>, matching the ER’s “No benefit reaches High”.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All twelve entries correspond exactly to the ER’s two Medium, six Low and four Speculative risk headings.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 574–583.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare headings only; hazard ratios, odds ratios and the manufacturer-co-authorship notes are all dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks entry.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	Line 574: <span data-qrs-var="risks_high" style="display: none"></span>, matching the ER’s “No risk reaches High”.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows and cadence both come from Monitoring Protocol & Defining Success (ER lines 488–500).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER table rows present with targets and rationales verbatim: 25-hydroxyvitamin D, serum retinol, fasting retinyl esters, omega-3 index, albumin-corrected serum calcium, ALT and INR.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 680 reproduces the ER’s baseline / 12-week / 6–12-month / annual schedule plus the anticoagulant clotting check at 4 weeks.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Taken from the ER’s “Qualitative markers worth tracking alongside the laboratory values” list (lines 502–510).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER qualitative markers present and verbatim, from night vision through to the smell check at each new bottle.

Issues 09/09/2026 06:56

Pass rate 100.00%. No issues found.

Issues 09/09/2026 06:50

1. 4.2 / 4.3 — Interaction label paraphrased: Caution item 7 (QRS line 560) reads “Additive vitamin A sources (retinyl palmitate, high-dose multivitamins, beef liver, other fish or krill oils)”, but the ER’s bold label (ER line 369) is “Additive supplements — vitamin A, retinyl palmitate, high-dose multivitamins, beef liver, other fish or krill oils”; the head phrase is invented and the list member “vitamin A” is absorbed into it rather than preserved.

Fixes 09/09/2026 06:50

1. 4.2 / 4.3 — Interaction label restored verbatim: Caution item 7 changed from “Additive vitamin A sources (retinyl palmitate, high-dose multivitamins, beef liver, other fish or krill oils)” to “Additive supplements (vitamin A, retinyl palmitate, high-dose multivitamins, beef liver, other fish or krill oils)”, matching the ER’s bold label and restoring “vitamin A” as a list member.